| Generic name | Idelalisib |
| Pronunciation | i-deh-luh-LIH-sib |
| Brand name(s), other common name(s) | Zydelig® |
| Drug type | Phosphoinositide 3-kinase (PI3K) delta inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Idelalisib is FDA approved to treat patients with
- Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
- Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
- Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.
- Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
Side effects needing medical attention
Diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, rash, neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations.
Idelalisib is being approved with a Boxed Warning alerting patients and healthcare professionals of the following fatal and serious adverse reactions: hepatotoxicity (liver damage caused by a drug), severe diarrhea or colitis, pneumonitis, and intestinal perforation.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.